✦ LIBER ✦

Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone ± thalidomide for systemic light-chain amyloidosis: results of a phase II trial

✍ Scribed by Adam D. Cohen; Ping Zhou; Joanne Chou; Julie Teruya-Feldstein; Lilian Reich; Hani Hassoun; Beth Levine; Daniel A. Filippa; Elyn Riedel; Tarun Kewalramani; Michael D. Stubblefield; Martin Fleisher; Stephen Nimer; Raymond L. Comenzo

Book ID: 108675406
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 203 KB
Volume: 139
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2007.06783.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Interim analysis of a phase II study of

Interim analysis of a phase II study of risk-adapted intravenous melphalan followed by adjuvant dexamethasone (D) and thalidomide (T) for newly diagnosed patients with systemic al amyloidosis (AL)

✍ A.D. Cohen; P. Zhou; L. Reich; S. Fircanis; L. Drake; C. Hedvat; J. Teruya-Felds 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 63 KB

High-dose melphalan with autologous stem

High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study

✍ Jolanta B. Perz; Stefan O. Schonland; Michael Hundemer; Arnt V. Kristen; Thomas 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB

Sequential vincristine, adriamycin, dexa

Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial

✍ Hye Jin Kim; Sung-Soo Yoon; Dong Soon Lee; Sang Kyun Sohn; Hyeon Seok Eom; Jung 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 184 KB

Predictors of survival in patients with

Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone

✍ D. Lebovic; J. Hoffman; B. M. Levine; H. Hassoun; H. Landau; Y. Goldsmith; M. S. 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB

Disabling Immune Tolerance by Programmed

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

✍ Armand, P.; Nagler, A.; Weller, E. A.; Devine, S. M.; Avigan, D. E.; Chen, Y.-B. 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 132 KB